There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and Seattle Genetics (SGEN) with bullish sentiments.
Alnylam Pharma (ALNY)
In a report issued on February 8, Gena Wang from Barclays maintained a Buy rating on Alnylam Pharma, with a price target of $140. The company’s shares closed on Friday at $77.69.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 21.5% and a 50.7% success rate. Wang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Logicbio Therapeutics Inc, and RegenXBio.
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $120, representing a 54.5% upside. In a report issued on January 28, Chardan Capital also maintained a Buy rating on the stock with a $150 price target.
See today’s analyst top recommended stocks >>
Seattle Genetics (SGEN)
In a report issued on February 8, Geoff Meacham from Barclays maintained a Buy rating on Seattle Genetics, with a price target of $85. The company’s shares closed on Friday at $65.02.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.6% and a 54.2% success rate. Meacham covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Vertex Pharmaceuticals, and Johnson & Johnson.
Currently, the analyst consensus on Seattle Genetics is a Moderate Buy with an average price target of $79, a 21.5% upside from current levels. In a report issued on February 8, H.C. Wainwright also maintained a Buy rating on the stock with a $98 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
